/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

US Stock Details

Get in-depth insights on US stocks, including fundamentals, financials, shareholding, peer comparison, and performance. Track key metrics, price trends, and market sentiment for informed decisions. Stay ahead with expert analysis and data-driven strategies at Motilal Oswal.

style
pb-0

CIDARA THERAPEUTICS INC

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0
$220.8 0.005(0.5%) CDTX at 04 Dec 2025 04:28 PM Biotechnology
Lowest Today 219.75
Highest Today 221.09
Today’s Open 219.76
Prev. Close 219.89
52 Week High 221.20
52 Week Low 15.22
Day’s Range: Low 219.75 High 221.09
52-Week Range: Low 15.22 High 221.20
1 day return -
1 Week return +0.49
1 month return +118.97
3 month return +239.8
6 month return +818.25
1 year return +1026.73
3 year return +1740.33
5 year return +360.08
10 year return -

Institutional Holdings

RA Capital Management, LLC 13.27

Bain Capital Life Sciences Investors, LLC 9.86

Point72 Asset Management, L.P. 6.03

Vivo Capital, LLC 5.17

COMMODORE CAPITAL LP 4.63

BlackRock Inc 4.37

Adage Capital Partners Gp LLC 4.34

TCG Crossover Management, LLC 3.97

Vanguard Group Inc 3.81

Morgan Stanley - Brokerage Accounts 3.48

Bvf Inc 3.10

Darwin Global Management, Ltd. 3.03

VR Adviser, LLC 2.52

HHG PLC 2.46

Vanguard Total Stock Mkt Idx Inv 2.34

Vestal Point Capital LP 1.97

Ikarian Capital, LLC 1.83

Soleus Capital Management, L.P. 1.83

Jefferies Financial Group Inc 1.77

iShares Russell 2000 ETF 1.59

Geode Capital Management, LLC 1.47

Citadel Advisors Llc 1.15

abrdn Healthcare Investors 0.71

Fidelity Small Cap Index 0.66

Vanguard Institutional Extnd Mkt Idx Tr 0.63

iShares Russell 2000 Value ETF 0.58

Fidelity Select Health Care 0.55

Invesco Dorsey Wright SmallCap Momt ETF 0.41

Fidelity Advisor Biotechnology I 0.41

Fidelity Extended Market Index 0.32

Vanguard Russell 2000 ETF 0.32

abrdn Life Sciences Investors 0.32

Fidelity Advisor Health Care I 0.32

Heptagon Driehaus US Micro Cap Eq C$ Acc 0.26

AXA Framlington Health Fund - R Income 0.24

State St Russell Sm Cap® Indx SL Cl I 0.23

Fidelity Select Biotechnology 0.22

Schwab Small Cap Index 0.17

NT R2000 Index Fund - NL 0.16

iShares Micro-Cap ETF 0.15

Market Status

Strong Buy: 2

Buy: 3

Hold: 0

Sell: 0

Strong Sell: 0

Fundamentals

Market Cap 6914.73 M

PB Ratio 16.3594

PE Ratio 0.0

Enterprise Value 6491.97 M

Total Assets 214.80 M

Volume 1264140

Company Financials

Annual Revenue FY23:56541000 56.5M, FY22:64288000 64.3M, FY21:49572000 49.6M, FY20:12067000 12.1M, FY19:20915000 20.9M

Annual Profit FY23:null 0.0M, FY22:64288000 64.3M, FY21:49572000 49.6M, FY20:12067000 12.1M, FY19:20915000 20.9M

Annual Net worth FY23:-30697000 -30.7M, FY22:-29799000 -29.8M, FY21:-43909000 -43.9M, FY20:-72373000 -72.4M, FY19:-40085000 -40.1M

Quarterly Revenue Q3/2025:0 0.0M, Q2/2025:0 0.0M, Q1/2025:0 0.0M, Q3/2024:0 0.0M, Q2/2024:302000 0.3M

Quarterly Profit Q3/2025:-45000000 -45.0M, Q2/2025:-27000 -0.0M, Q1/2025:-49000 -0.0M, Q3/2024:null 0.0M, Q2/2024:245000 0.2M

Quarterly Net worth Q3/2025:-83233000 -83.2M, Q2/2025:-25718000 -25.7M, Q1/2025:-23480000 -23.5M, Q3/2024:-15535000 -15.5M, Q2/2024:-89410000 -89.4M

Fund house & investment objective

Company Information Cidara Therapeutics, Inc. operates as a biotechnology company that focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company's product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also develops its Cloudbreak platform that enables development of novel drug-Fc conjugates, that includes CD388, a potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase 1 and Phase 2a clinical trials. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. Cidara Therapeutics, Inc. was incorporated in 2012 and is based in San Diego, California.

Organisation Biotechnology

Employees 38

Industry Biotechnology

CEO Dr. Jeffrey L. Stein Ph.D.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow